COVID-19 (Coronavirus) Update

As the level of COVID-19 infections begins to stabilize in our community, we are starting to reschedule appointments, surgeries, and procedures that were delayed during the pandemic. Learn more about how Duke Health is committed to keeping you safe. Visitor restrictions remain in effect. 

ECOG-ACRIN EA6174 (Merkel Cell Carcinoma) - Clinical Trial

What is the Purpose of this Study?

We are doing this study to learn if we can lower the chance of your cancer growing back by adding the study drug (Pembrolizumab) after your surgery.
What is the Condition Being Studied?
Stage I -IIIB Merkel Cell Carcinoma (MCC) that has been removed by surgery

Who Can Participate in the Study?

Adults with Merkel cell carcinoma (MCC).

Age Group
Adults

What is Involved?

If you choose to join the study you will:
-Either get the study drug, Pembrolizumab, after surgery, OR
-Be observed after surgery for up to 1 year (no study drug)
-Complete regular follow-up appointments with your doctor every 6 months for 5 years

Study Details

Full Title
ECOG-ACRIN EA6174 STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab - A Phase III Trial
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00103859
NCT: NCT03712605
Phase
Phase III
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698